[1]李中万,徐绍俊,杨广钢,等.健肾方联合碳酸钙D3咀嚼片(Ⅱ) 治疗绝经后骨质疏松症肾阳虚证[J].中医正骨,2018,30(08):11-15.
　LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健肾方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(08):11-15.
点击复制

健肾方联合碳酸钙D3咀嚼片(Ⅱ) 治疗绝经后骨质疏松症肾阳虚证()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第30卷
期数:
2018年08期
页码:
11-15
栏目:
临床研究
出版日期:
2018-08-20

文章信息/Info

Title:
Oral application of Jianshen Fang(健肾方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome
作者:
李中万; 徐绍俊; 杨广钢; 姚丽云; 付小勇; 潘永雄
广东省广州市正骨医院,广东 广州 510045
Author(s):
LI Zhongwan; XU Shaojun; YANG Guanggang; YAO Liyun; FU Xiaoyong; PAN Yongxiong
Guangzhou Orthopedic Hospital,Guangzhou 510045,Guangdong,China
关键词:
骨质疏松; 绝经后;  肾阳虚;  健肾方;  骨密度;  雌二醇;  骨保护素;  胰岛素样生长因子Ⅰ
Keywords:
osteoporosis;  postmenopausal;  kidney-yang deficiency;  Jianshen Fang;  bone density;  estradiol;  osteoprotegerin;  insulin-like growth factor I
摘要:
观察健肾方联合碳酸钙D3咀嚼片(Ⅱ)治疗绝经后骨质疏松症(postmenopausal osteoporosis,PMOP)肾阳虚证的临床疗效和安全性。方法:选取80例符合要求的PMOP肾阳虚证患者,随机分为2组,每组40例。健肾方组采用口服健肾方联合碳酸钙D3咀嚼片(Ⅱ)治疗,阿仑膦酸钠组采用口服阿仑膦酸钠片联合碳酸钙D3咀嚼片(Ⅱ)治疗,共治疗6个月。分别于治疗前和治疗结束后测定患者的骨密度、疼痛程度、血清雌二醇(Estradiol,E2)、骨保护素和胰岛素样生长因子Ⅰ(insulin-like growth factor Ⅰ, IGF-Ⅰ)含量,观察不良反应的发生情况。结果:健肾方组2例出现肝功能指标异常,2例出现肾功能指标异常; 阿仑膦酸钠组1例出现肝功能指标异常,1例出现肾功能指标异常。对于出现不良反应的患者均立即停止使用当前药物,给予护肝及保护肾功能等对症处理后,患者的肝肾功能指标均在2周内恢复至正常范围。2组患者的不良反应发生率比较,差异无统计学意义(χ2=0.180,P=0.671)。治疗前2组患者的骨密度比较,差异无统计学意义(t=1.014,P=0.314); 治疗结束后2组患者的骨密度均较治疗前增加(-2.69±0.12,-2.09±0.22,t=14.343,P=0.000; -2.72±0.13,-2.37±0.09,t=14.038,P=0.000),健肾方组的骨密度高于阿仑膦酸钠组(t=6.931,P=0.000)。治疗前2组患者的疼痛视觉模拟量表(visual analogue scale,VAS)评分比较,差异无统计学意义(t=0.465,P=0.644); 治疗结束后2组患者的疼痛VAS评分均较治疗前降低[(4.53±0.94)分,(2.33±0.68)分,t=11.366,P=0.000;(4.42±1.03)分,(3.21±0.87)分,t=5.522,P=0.000],健肾方组的VAS评分低于阿仑膦酸钠组(t=4.841,P=0.000)。治疗前2组患者的血清E2含量比较,差异无统计学意义(t=0.511,P=0.611); 治疗结束后健肾方组的血清E2含量较治疗前升高[(50.91±6.24)pmol·L-1,(62.88±9.02)pmol·L-1,t=6.546,P=0.000]; 阿仑膦酸钠组血清E2含量与治疗前相比,差异无统计学意义[(50.17±6.31)pmol·L-1,(50.88±8.16)pmol·L-1,t=0.425,P=0.672]; 治疗结束后,健肾方组的血清E2含量高于阿仑膦酸钠组(t=6.006,P=0.000)。治疗前2组患者的血清骨保护素含量比较,差异无统计学意义(t=0.348,P=0.729); 治疗结束后2组患者的血清骨保护素含量均较治疗前升高[(140.76±14.97)pg·mL-1,(160.18±15.70)pg·mL-1,t=5.371,P=0.000;(139.55±14.99)pg·mL-1,(146.68±15.68)pg·mL-1,t=2.027,P=0.046],健肾方组的血清骨保护素含量高于阿仑膦酸钠组(t=3.701,P=0.000)。治疗前2组患者的血清IGF-Ⅰ含量比较,差异无统计学意义(t=0.839,P=0.404); 治疗结束后2组患者的血清IGF-Ⅰ含量均较治疗前升高[(25.19±8.34)μg·L-1,(35.81±9.48)μg·L-1,t=5.042,P=0.000;(23.53±8.74)μg·L-1,(28.87±10.29)μg·L-1,t=2.440,P=0.017],健肾方组的血清IGF-Ⅰ含量高于阿仑膦酸钠组(t=3.012,P=0.004)。结论:健肾方联合碳酸钙D3咀嚼片(Ⅱ)能提高PMOP肾阳虚证患者血清E2、骨保护素及IGF-Ⅰ含量,增加患者的骨密度、减轻疼痛程度,其效果优于阿仑膦酸钠片联合碳酸钙D3咀嚼片(Ⅱ)治疗,而且具有较高的安全性。
Abstract:
To observe the clinical curative effects and safety of oral application of Jianshen Fang(健肾方,JSF)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis(PMOP)with kidney-yang deficiency syndrome.Methods:Eighty patients with kidney-yang deficiency type PMOP were enrolled in the study and randomly divided into 2 groups,40 cases in each group,and were treated with oral application of JSF and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)(JSFgroup)and oral application of alendronate sodium tablets and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)(alendronate sodium group)respectively for consecutive 6 months.Bone density,pain degree and serum contents of Estradiol(E2),osteoprotegerin(OPG)and insulin-like growth factor Ⅰ(IGF-Ⅰ)were measured and compared between the 2 groups before treatment and after the end of the treatment respectively,and the incidence rate of adverse reactions was observed.Results:Abnormal liver function indexes were found in 2 patients in JSF group and 1 patient in alendronate sodium group,and abnormal kidney function indexes were found in 2 patients in JSF group and 1 patient in alendronate sodium group.The drugs which caused adverse effects were withdrew immediately and liver and kidney protective agents were used,and the liver and kidney function recovered from injury 2 weeks later.There was no statistical difference in the incidence rate of adverse reactions between the 2 groups(χ2=0.180,P=0.671).There was no statistical difference in the bone density between the 2 groups before the treatment(t=1.014,P=0.314).The bone density increased after the end of the treatment compared to pretreatment in the 2 groups(-2.69+/-0.12 vs -2.09+/-0.22,t=14.343,P=0.000; -2.72+/-0.13 vs -2.37+/-0.09,t=14.038,P=0.000),and was higher in JSF group compared to alendronate sodium group(t=6.931,P=0.000).There was no statistical difference in pain visual analogue scale(VAS)scores between the 2 groups before the treatment(t=0.465,P=0.644).The pain VAS scores decreased after the end of the treatment compared to pretreatment in the 2 groups(4.53+/-0.94 vs 2.33+/-0.68 points,t=11.366,P=0.000; 4.42+/-1.03 vs 3.21+/-0.87 points,t=5.522,P=0.000),and was lower in JSF group compared to alendronate sodium group(t=4.841,P=0.000).There was no statistical difference in serum contents of E2 between the 2 groups before the treatment(t=0.511,P=0.611).The serum contents of E2 increased after the end of the treatment compared to pretreatment in JSF group(50.91+/-6.24 vs 62.88+/-9.02 pmol/L,t=6.546,P=0.000).There was no statistical difference in serum contents of E2 between pre-treatment and post-treatment in alendronate sodium group(50.17+/-6.31 vs 50.88+/-8.16 pmol/L,t=0.425,P=0.672).The serum contents of E2 were higher in JSF group compared to alendronate sodium group after the end of the treatment(t=6.006,P=0.000).There was no statistical difference in serum contents of OPG between the 2 groups before the treatment(t=0.348,P=0.729).The serum contents of OPG increased after the end of the treatment compared to pretreatment in the 2 groups(140.76+/-14.97 vs 160.18+/-15.70 pg/mL,t=5.371,P=0.000; 139.55+/-14.99 vs 146.68+/-15.68 pg/mL,t=2.027,P=0.046),and were higher in JSF group compared to alendronate sodium group(t=3.701,P=0.000).There was no statistical difference in serum contents of IGF-Ⅰbetween the 2 groups before the treatment(t=0.839,P=0.404).The serum contents of IGF-Ⅰincreased after the end of the treatment compared to pretreatment in the 2 groups(25.19+/-8.34 vs 35.81+/-9.48 μg/L,t=5.042,P=0.000; 23.53+/-8.74 vs 28.87+/-10.29 μg/L,t=2.440,P=0.017),and were higher in JSF group compared to alendronate sodium group(t=3.012,P=0.004).Conclusion:Oral application of JSF and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)can increase the serum contents of E2,OPG and IGF-Ⅰand improve bone density and alleviate pain in patients with kidney-yang deficiency type PMOP,and its curative effect is better than that of oral application of alendronate sodium tablets and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ),moreover,it has high safety.

参考文献/References:

[1] BLACK DM,ROSEN CJ.Clinical practice.Postmenopausal osteoporosis[J].N Engl J Med,2016,374(3):254-262.
[2] 徐绍俊,黄建烽,邵敏,等.雌激素受体α基因甲基化与骨质疏松关系的研究进展[J]. 中国骨质疏松杂志, 2017, 23(3):388-391.
[3] MANOLAGAS SC,O'BRIEN CA,ALMEIDA M.The role of estrogen and androgen receptors in bone health and disease[J].Nat Rev Endocrinol,2013,9(12):699-712.
[4] 刘刚,唐瑭,刘晶晶.阿仑膦酸钠联合钙尔奇D治疗老年骨质疏松62例[J].中国老年学杂志,2012,32(18):4070-4071.
[5] 罗建,聂桂峰,黄小虎,等.固力康联合钙尔奇D在骨质疏松症合并股骨粗隆间骨折治疗中的疗效及其对骨代谢指标的影响[J].安徽医药,2017,21(6):1101-1105.
[6] 中国老年学学会骨质疏松委员会中医药与骨病学科组.中医药防治原发性骨质疏松症专家共识(2015)[J].中国骨质疏松杂志,2015,21(9):1023-1028.
[7] 徐绍俊,黄建烽,邵敏,等.补肾方剂对绝经后骨质疏松症大鼠的影响及其作用机制研究[J].中药新药与临床药理,2017,28(5):588-593.
[8] CRANDALL CJ,NEWBERRY SJ,DIAMANT A,et al.Comparative effectiveness of pharmacologic treatments to prevent fractures:an updated systematic review[J].Ann Intern Med,2014,161(10):711-723.
[9] 赵文昌,宋丽军,温凯航,等.淫羊藿抗骨质疏松症的研究进展[J].中医药导报,2012,9(25):20-21.
[10] 周菊峰,黄兰芳,胡伟,等.气相色谱/质谱和化学计量学解析法用于千斤拔挥发性成分的分析[J].药物分析杂志,2011,31(7):1308-1312.
[11] 徐林,傅忠国,易斌,等.阿仑膦酸钠治疗绝经后骨质疏松疗效及安全性分析[J].中国药房,2000,11(1):33-34.
[12] 周汉华,刘晓龙,钱海兵,等.不同寄主上的桑寄生药材毒性的比较研究[J].中国实验方剂学杂志,2013,19(24):274-277.

相似文献/References:

[1]李林军.应用膨胀式椎弓根螺钉内固定治疗合并骨质疏松的 胸腰椎退行性疾病[J].中医正骨,2015,27(08):49.
[2]李学朋,朱立国.骨疏康胶囊对去卵巢大鼠骨小梁的影响[J].中医正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康胶囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):12.
[3]陈冠军,陈扬,庄汝杰.可灌注骨水泥椎弓根螺钉系统 在老年腰椎疾患手术中的应用[J].中医正骨,2015,27(02):40.
[4]王丹辉,贲越,韩梅.林蛙油治疗绝经后骨质疏松症的临床研究[J].中医正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):27.
[5]黄建华,黄建武,李慧辉,等.加味左归丸对绝经后骨质疏松症肝肾不足证 患者骨密度的影响[J].中医正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):19.
[6]项旻,杨虹,林爱菊,等.绝经后2型糖尿病患者骨质疏松与血微量元素的关系研究[J].中医正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):20.
[7]史晓林,李春雯,张志强.弱阳离子磁珠分离技术和基质辅助激光解吸电离飞行时间质谱技术在原发性Ⅰ型骨质疏松症血清标志蛋白筛选中的应用[J].中医正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):5.
[8]李明,徐明雄,冯左基,等.自拟壮骨方治疗绝经后骨质疏松症的疗效及作用机制研究[J].中医正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):21.
[9]陈俊杰,李晴晴,夏瑢.脂代谢及血清内脂素水平与绝经后骨质疏松症的 相关性研究[J].中医正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(08):16.
[10]许超,肖鲁伟,吴承亮.绝经后女性骨质疏松症辨证分型与抑郁焦虑的关系研究[J].中医正骨,2011,23(12):3.
　XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(08):3.
[11]韩艳,温利平,刘娜,等.补肾活血方对去卵巢大鼠骨代谢及骨密度的影响[J].中医正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(补肾活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):7.
[12]欧国峰,刘鑫,董博,等.绝经后骨质疏松症的免疫学研究进展[J].中医正骨,2016,28(08):70.
[13]施振宇,刘钟,陈文亮,等.中医综合疗法防治绝经后骨量减少的多中心临床研究[J].中医正骨,2017,29(04):1.
　SHI Zhenyu,LIU Zhong,CHEN Wenliang,et al.A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(08):1.
[14]梁文娜,李西海,李灿东.血清microRNA与绝经后骨质疏松症肾虚证的关系[J].中医正骨,2017,29(10):53.
[15]梁文娜,李西海,胡柳,等.二至丸抑制绝经后骨质疏松大鼠骨代谢紊乱的作用机制研究[J].中医正骨,2017,29(11):1.
　LIANG Wenna,LI Xihai,HU Liu,et al.Study on mechanism of action of Erzhi Wan(二至丸)in inhibiting bone metabolism disorder in rats with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(08):1.
[16]刘晨,李兴勇,姚兴璋,等.绝经后骨质疏松症的流行病学概况及发病机制研究进展[J].中医正骨,2018,30(03):52.
[17]杨依然,刘钟,毛一凡,等.酪蛋白激酶-2相互作用蛋白1基于磷脂酰肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白通路参与绝经后骨质疏松症发生发展过程中细胞自噬的机制[J].中医正骨,2018,30(04):59.
[18]曹俊青,郑剑南,张麟.右归丸联合阿仑膦酸钠口服治疗绝经后骨质疏松症肾阳虚证的临床研究[J].中医正骨,2018,30(05):20.
　CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右归丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(08):20.
[19]赵凡,刘全,吴连国.口服强骨饮联合碳酸钙D3片治疗绝经后骨质疏松症的临床研究[J].中医正骨,2019,31(04):26.
　ZHAO Fan,LIU Quan,WU Lianguo.Oral applications of Qianggu Yin(强骨饮)and calcium carbonate and Vitamin D3 tablets for treatment of postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(08):26.
[20]史晓林,杨依然,刘钟,等.基于蛋白质组学方法分析绝经后骨质疏松症全血差异蛋白[J].中医正骨,2019,31(06):7.
　SHI Xiaolin,YANG Yiran,LIU Zhong,et al.Analysis of proteins which are differentially expressed in whole blood of patients with postmenopausal osteoporosis using proteomics approach[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(08):7.

备注/Memo

备注/Memo:
基金项目:广东省中医药局科研课题(20172116) 通讯作者:徐绍俊 E-mail:290936029@qq.com
更新日期/Last Update: 2018-08-31